Safety and Efficacy of High Intensity Focused Ultrasound in Solar Lentigo: A Self-controlled Study

Nanjing Medical University

Status: Active, not recruiting

Conditions: Solar Lentigo

Treatments: Device: High intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China)

Study type: Observational

Funder types: Other

Identifiers

NCT06288607

2023-SR-708

Details and patient eligibility

About

This trial is a single-center, prospective self-controlled study. The study proposes to recruit 30 patients with solar lentigo on both sides of the face. Patients are randomly assigned to be treated with high-intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China) on one side, and the other side is not treated. The Lab* values of the lesion area and the area around the lesion are detected separately using 3nh HIGH-QUALITY COLORMETER colorimeter (Konica-Minolta Company, Japan), and skin lesion images are collected with dermatoscope and VISIA® (Canfield Company, USA). Measurements of Lab* values and related images at the same location, along with adverse events, physician and subjective global aesthetic improvement scale scores are recorded before and at week2, week 4, week6. At the end of the follow-up on the treatment side, the same parameter treatment is provided for the untreated side, and the corresponding observation items are recorded for the patient before treatment, and at week2, week4, and week6 respectively.

Enrollment: 30 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. adults between 18 and 60 years old, regardless of gender;
2. comply the clinical diagnostic criteria for solar lentigo on both sides of the face;
3. patients understand and are willing to participate in this clinical trial and voluntarily sign an informed consent form;

Exclusion criteria

1. Women who are pregnant or breastfeeding, or who plan to become pregnant during the trial period;
2. those who are allergic to medical condensation gel;
3. those with photosensitive diseases, immune deficiencies, or those who are taking immunosuppressants;
4. those with diabetes, malignant tumors, epilepsy, severe liver, kidney, or heart conditions, or any other acute or chronic medical history that could potentially affect the effectiveness or safety outcomes of this trial;
5. those with scar physique;
6. those with inflammatory or infectious skin diseases;
7. those who have systemically used retinoic acid in the last six months or topically applied retinoic acid drugs in the last three months, or have a history of sun exposure in the four weeks prior to treatment;
8. those who have undergone high-intensity focused ultrasound treatment within the last six months;
9. Those with serious heart, brain, lung, liver and kidney function damage; Pregnant and lactating women;
10. Those who have a history of psychological and mental illness, recent history of alcoholism or drug abuse;
11. patients who are unwilling to sign the informed consent and who are unwilling to cooperate.

Trial design

30 participants in 1 patient group

Patients

Description:

Patients with solar lentigo

Treatment:

Device: High intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China)